Healthcare Industry News: ultrasound
News Release - August 30, 2017
SonaCare Medical Delivers Compatability With bkFusionCHARLOTTE, N.C., Aug. 30, 2017 -- (Healthcare Sales & Marketing Network) -- SonaCare Medical, the leading developer and manufacturer of high intensity focused ultrasound (HIFU) technologies, announces today the successful collaboration with BK ultrasound, achieving compatibility between bkFusion and SonablateŽ planning software for the ablation of prostate tissue.
Earlier this year, BK ultrasound, powered by Analogic, introduced bkFusion, an MRI-fusion imaging software which integrates fully into both its bk3000 and bk5000 premium ultrasound systems. To develop bkFusion, BK ultrasound partnered with MIM Software Inc., a world leader in the development and deployment of medical imaging and analysis software applications in the Radiology and Radiation Oncology fields. This innovative software builds on MIM's unique Predictive Fusion technology that enables urologists to biopsy MRI-defined targets in the prostate precisely.
During a focused ultrasound prostate ablation therapy, Sonablate uses bkFusion to fuse annotated MRI data with intraoperative ultrasound images. The incorporation of MRI imaging into the HIFU ablation treatment planning process enhances Sonablate's ability to precisely target specific regions within the prostate gland identified for ablation.
"We were pleased to build on our partnership with MIM Software Inc. by developing additionally a collaboration with BK ultrasound," comments SonaCare Medical CEO, Dr. Mark Carol. "The addition of bkFusion to our portfolio of fusion integration options is further demonstration of SonaCare Medical's commitment to serve better our community of doctors and hospitals who want to make the most of their ultrasound platform investment. Collaborating with targeted biopsy vendors who are the best in their field allows us to combine their expertise in fusion with our leading HIFU technology in order to offer the most precise prostate ablation possible."
SonablateŽ continues to be the only HIFU ablation device integrated with the majority of leading fusion platforms and was the first device to receive regulatory authorization from the FDA for the focused ultrasound ablation of prostate tissue. Since its introduction over 15 years ago, SonablateŽ technology has been used around the world on over 15,000 patients in over 30 countries, including approximately 1,500 U.S. men who have had this procedure performed in the U.S.
About SonaCare Medical, LLC
SonaCare Medical is a world leader in minimally-invasive high intensity focused ultrasound (HIFU) technologies. SonaCare Medical is committed to developing focused ultrasound related technologies that support precise and innovative procedures for the treatment of a range of medical conditions. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures medical devices, including the following: SonablateŽ, which has 510(K) clearance in the U.S.; SonablateŽ 500, which has CE Marking and has obtained regulatory authorization in more than 49 countries outside the U.S.; SonathermŽ laparoscopic HIFU surgical ablation system, which has 510(K) clearance in the U.S., has CE Marking and has obtained regulatory authorization in more than 30 countries outside the U.S.
For additional information, visit www.SonaCareMedical.com
Forward Looking Statements
The Company's forward-looking statements are based on management's current expectations and assumptions regarding the Company's business and performance, the economy and other future conditions and forecasts of future events, circumstances and results. As with any projection or forecast, forward-looking statements are inherently susceptible to uncertainty and changes in circumstances. The Company's actual results may vary materially from those expressed or implied in its forward-looking statements. Any forward-looking statement made by the Company speaks only as of the date on which it is made. The Company is under no obligation to, and expressly disclaims any obligation to, update or alter its forward-looking statements, whether as a result of new information, subsequent events or other factors.
Source: SonaCare Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.